PIK3CA and breast cancer: The publication of results from the pivotal phase III SOLAR-1 trial eventually led to the approval of alpelisib in combination with fulvestrant for patients with PIK3CA-mutant, ER+ advanced breast cancer, and prior exposure to ET [85].